Viread, Tenofovir News

Investigators analysed immunological outcomes in over 72,000 people starting first-line treatment in southern Africa.

Some Asian people with chronic hepatitis B treated with pegylated interferon may experience better outcomes on certain measures than Caucasians, though overall response rates are similar, according to a comparative analysis presented at the EASL International Liver Congress last month in Amsterdam.

A combination of tenofovir and emtricitabine suppressed hepatitis B virus replication more than tenofovir alone over 4 years for people with inactive or immune-tolerant disease, researchers reported at the EASL International Liver Congress this week in Amsterdam.

Gilead Sciences, Inc. announced today its results of operations for the quarter ended March 31, 2013.

The HIV antiretrovirals Viread and Emtriva , which are typically combined as Truvada, can suppress the hepatitis B virus in three-quarters of those with "immune-tolerant" infection, MedPage Today reports.

Gilead's profits and earnings in first quarter of 2013 are tied to price increases on key AIDS drugs, and the evergreening of older drugs into the pricey new combination Stribild and a Hep C drug priced so high it could impede access to medications through government programs, including cash-strapped AIDS Drug Assistance Programs AHF says Gilead ... (more)

A combination of tenofovir and emtricitabine suppressed hepatitis B virus replication more than tenofovir alone over 4 years for people with inactive or immune-tolerant disease, researchers reported at the EASL International Liver Congress this week in Amsterdam.

Long-term treatment with tenofovir lowered the risk of developing hepatocellular carcinoma among people with chronic hepatitis B, with a notable divergence from expected rates after about 5 years, according to a report presented at the 48th International Liver Congress this week in Amsterdam.